Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA22029O6" target="_blank" >RIV/61988987:17110/21:A22029O6 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/21:E0108656 RIV/00216208:11110/21:10427300 RIV/00064165:_____/21:10427300
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S147020452030680X" target="_blank" >https://www.sciencedirect.com/science/article/pii/S147020452030680X</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(20)30680-X" target="_blank" >10.1016/S1470-2045(20)30680-X</a>

Result language
angličtina
Original language name
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Original language description
Background Improved therapeutic options are needed for patients with relapsed or relapsed and refractory multiple myeloma. Subcutaneous bortezomib has replaced intravenous bortezomib as it is associated with a more favourable toxicity profile. We investigated the activity and safety of three different dosing regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone for this indication.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)